Werewolf Therapeutics to merge with Ambros in stock deal
Werewolf Therapeutics says stockholders would own 6.8% of the combined company, Ambros stockholders 71.7% and private placement investors 21.5%, with closing expected by Q1 2027 subject to approvals.
HOWL (more) Werewolf Therapeutics - stockholders to own 6.8%, ambros stockholders 71.7%, private placement investors 21.5% of combined Co Werewolf Therapeutics - deal expected to close by Q1 2027 subject to approvals - Combined company to be led by ambros Therapeutics leadership team with Joseph (jay) hagan as CEO - Stockholders of ambros will receive newly issued shares of Co's stock stock pursuant to a Formula set forth in deal agreement - Ambros expects combined Co to be fully funded through topline results from pivotal crps-rise phase 3 clinical trial - Exchange is based on implied value of ambros of $500M (before private placement) and implied value of Co of $47.5M